Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell count

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,331 result(s) found for: Cell count. Displaying page 1 of 167.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-022812-37 Sponsor Protocol Number: ORH/PID/6265 Start Date*: 2011-06-07
    Sponsor Name:Oxford University Hospitals NHS Trust
    Full Title: A phase 2 trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
    Medical condition: Diffuse Large B-cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004568-37 Sponsor Protocol Number: INV543 Start Date*: 2018-11-30
    Sponsor Name:Nova Laboratories Limited
    Full Title: A prospective open label, pharmacokinetic study of an oral hydroxyurea solution in children with sickle cell anemia
    Medical condition: Sickle Cell Anaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-005566-39 Sponsor Protocol Number: 06_DOG07_64 Start Date*: 2008-03-05
    Sponsor Name:Christie Hospital NHS Foundation Trust
    Full Title: Concurrent chemoradiotherapy for stage III non small cell lung cancer followed by consolidation pemetrexed: a phase II study
    Medical condition: Non-small cell lung cancer, stage III
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002987-24 Sponsor Protocol Number: 152CL201 Start Date*: 2007-06-25
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclopho...
    Medical condition: Relapsed Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) SK (Completed) PT (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007139-26 Sponsor Protocol Number: S075LBH501 Start Date*: 2008-04-17
    Sponsor Name:SENDO TECH
    Full Title: A phase II study of the histone deacetylase inhibitor Panobinostat (LBH589) in patients with advanced Small Cell Lung Cancer (SCLC)
    Medical condition: SCLC patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041070 Small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003485-39 Sponsor Protocol Number: NN7533-4470 Start Date*: 2022-07-19
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease
    Medical condition: Sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003796-20 Sponsor Protocol Number: HOVON 77 Start Date*: 2007-01-03
    Sponsor Name:HOVON Foundation
    Full Title: Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission f...
    Medical condition: patients with diffuse Large B-Cell lymphoma, CD20-positive
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001117-34 Sponsor Protocol Number: APL-B-013-02 Start Date*: 2004-10-13
    Sponsor Name:Pharma Mar S.A.
    Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.
    Medical condition: Aggressive non-Hodgkin’s Lymphoma.For aggressive NHL patient cure is still the target of therapy and a CR is a prerequisite to achieve this goal. Salvage therapy needs more aggressive experimental ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005245-37 Sponsor Protocol Number: M06-880 Start Date*: 2008-04-17
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002173-26 Sponsor Protocol Number: VX21-CTX001-151 Start Date*: 2021-10-05
    Sponsor Name:VERTEX PHARMACEUTICALS INCORPORATED
    Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease
    Medical condition: Severe Sickle Cell Disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004722-27 Sponsor Protocol Number: ICT-BEM-2004-01 Start Date*: 2005-05-12
    Sponsor Name:Instituto Científico y Tecnológico de Navarra, S.A.
    Full Title: Randomised, open, multicenter, sequential trial assessing the safety and efficacy of bemiparin on the response to the treatment in patients diagnosed with localized small cell carcinoma of the lung.
    Medical condition: Small cell carcionoma of the lung medDRA CLASSIFICATION CODE: PT 10041071
    Disease: Version SOC Term Classification Code Term Level
    4.0 10041071 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007434-20 Sponsor Protocol Number: RV0272 Start Date*: 2008-03-19
    Sponsor Name:Deptartment of Hematology, Karolinska University Hospital
    Full Title: Phase I (II) study of the combination of lenalidomide and alemtuzumab in patients with chemotherapy refractory chronic lymphocytic leukemia (CLL)
    Medical condition: Refractory or relapsed chronic lymphocytic leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002101-19 Sponsor Protocol Number: CACZ885X2206 Start Date*: 2016-11-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult pa...
    Medical condition: Sickle cell anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017093-20 Sponsor Protocol Number: INT 70/09 Start Date*: 2010-01-25
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase 2 study with the multi-targeted tyrosine-kinase inhibitor Pazopanib (GW786034) for patients with relapsed or refractory urothelial cancer
    Medical condition: Urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064467 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004851-39 Sponsor Protocol Number: 109/2006/U/Sper Start Date*: 2006-10-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENT TREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN) IN ELDERLY ( 60 YEARS) PATIENTS WITH DI...
    Medical condition: DIFFUSE LARGE BCELL LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006566-42 Sponsor Protocol Number: SIRN Start Date*: 2007-09-03
    Sponsor Name:Universität Mainz, III. Medizinische Klinik
    Full Title: Sorafenib in Resected NSCLC (SIRN) - A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment following Resection of Non-small Cell Lung Carcinoma (NSCLC) in Patie...
    Medical condition: Patients with histologically confirmed diagnosis of NSCLC pathological stages I, II or III A. Patients must have completely resected disease and may not be treated with prior chemotherapy. Patients...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001058-16 Sponsor Protocol Number: NLG-LBC-07 Start Date*: 2017-02-15
    Sponsor Name:Nordic Lymphoma Group
    Full Title: A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma.
    Medical condition: Relapsed/refractory diffuse large B-cell lymphoma, including transformed low grade lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-016378-34 Sponsor Protocol Number: MI-CP204 Start Date*: 2010-06-30
    Sponsor Name:MedImmune LLC
    Full Title: An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
    Medical condition: Relapsed or refractory advanced B-cell malignancies: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin’s lymphoma (NHL) (subtypes: follicular lymphoma (FL)...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000498-40 Sponsor Protocol Number: CRAD001N2301 Start Date*: 2009-06-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching pla...
    Medical condition: Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) AT (Completed) IT (Completed) DE (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-023869-21 Sponsor Protocol Number: ML25575 Start Date*: 2011-02-09
    Sponsor Name:Roche Oy
    Full Title: A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal ...
    Medical condition: Locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:48:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA